clinical trials

Columbus Oncology & Hematology is an independently-owned, physician-owned private practice of hematology and medical oncology experts serving central Ohio and surrounding communities since 1987. Its board-certified physicians treat many types of cancer and blood disorders, working with oncology pharmacists, advanced practice providers, and support staff across three community-based Cancer Centers and a retail pharmacy.

diagnostic serviceshematologyimaginginfusionmedical oncologyspecialty pharmacy

Comfort Talk® (Hypnalgesics d/b/a Comfort Talk) is a 100% Woman-Owned Small Business established in 2006. It offers an innovative, research-based, drug-free method for front line healthcare providers to reduce patient pain and anxiety from the waiting room to the exam table, while improving patient satisfaction, operational efficiency, and staff resilience. The techniques were developed by interventional radiologist Dr. Elvira Lang over 25 years of research and tested in over 130,000 patient encounters.

hypnotic languagelive webinar trainingonline trainingrapid rapport and word choice techniquesself-hypnotic relaxationtrainer trainingtraining healthcare professionals

Common Pharma, Inc. is a pharmaceutical company developing medicine for hard-to-treat diseases. Its primary focus is a novel class of compounds with preclinical effectiveness in treating xenograft tumors and blocking IL-6 overexpression. Its patented molecules have shown anti-bacterial efficacy against P. Acne and MRSA, and it has a topical program for dermal conditions with clinical efficacy in reducing facial blemishes.

drug developmentpreclinical research

Compass Pathways is a mental health care company developing a new clinical standard designed to open and relieve the mind through psychedelic treatment. It describes itself as running the world's largest classic psychedelic clinical program, advancing new options for people living with difficult-to-treat mental health conditions through rigorous science and compassion.

psychedelic treatment research

Conquest Research is a regional clinical research network founded in Central Florida with six locations across Florida, Virginia, and Georgia. It conducts clinical trials across therapeutic areas including neurology, metabolic disorders, dermatology, gastrointestinal, orthopedics, psychiatry, rheumatology, and sleep disorders. It offers services directly to pharmaceutical companies and to physician practices interested in conducting clinical trials.

community outreachmulti-site clinical research networkpatient recruitmentpreclinical development research

Constant Therapeutics LLC is a private biopharmaceutical company focused on the development of treatments impacting the Alternative Renin-Angiotensin System. It develops peptide and small molecule drugs, including its lead peptide product TXA127, a pharmaceutical formulation of the natural human peptide angiotensin-(1-7). The company targets diseases with significant unmet needs including Duchenne Muscular Dystrophy, Epidermolysis Bullosa, and Ischemic Stroke.

drug development

Contraline is a biotechnology company developing effective, safe, and reversible contraceptive options for men and couples worldwide. Its investigational male contraceptives include NES/T, a daily topical gel designed to pause sperm production, and ADAM, a non-hormonal hydrogel implant injected into the vas deferens to block sperm.

contraceptive product development

Corcept Therapeutics is a biopharmaceutical company focused on modulating cortisol activity at the glucocorticoid receptor (GR) to treat serious diseases. It has discovered more than 1,000 selective proprietary cortisol modulators and received FDA approval in 2012 of Korlym (mifepristone), the first approved treatment for hypercortisolism (Cushing syndrome). It conducts more than 30 ongoing studies across endocrinology, oncology, metabolism, and neurology.

research and development of cortisol modulators

CorePath is a CLIA-certified and CAP-accredited laboratory headquartered in San Antonio, Texas, offering cancer diagnosis including morphologic evaluation, second opinion, immunohistochemistry, multicolor flow cytometry, cytogenetics, FISH, molecular genetics, next generation sequencing and liquid biopsy testing. Its team of Board Certified Pathologists and clinical lab scientists provides diagnosis for cancer patients in the United States and worldwide.

biomarkers analysiscytogeneticsFISHhistologyimmunohistochemistryliquid biopsymulticolor flow cytometrynew test and platform validationnext-generation sequencingtissue banking

Correa Research Center conducts clinical trials with care, advancing medical knowledge while prioritizing participant safety and comfort. The center is dedicated to ethical research, ensuring transparency and support for every participant throughout their journey, and its expert team ensures compliance with all medical regulations.

clinical researchMedical Research

Cortene is a clinical stage biopharmaceutical company developing a patent-protected, peptide-based treatment for brain-centric acquired chronic diseases (ACDs). Its hypothesis centers on dysregulated serotonin signals driven by upregulated CRFR2, which it aims to reverse using agonist-mediated receptor endocytosis. The hypothesis has been partially proven in a proof-of-concept Phase 2 clinical trial, and the company plans trials in Parkinson's and Alzheimer's.

drug developmentpeptide manufacturing and formulationRegulatory Affairs

CPCC-RESEARCH is a clinical research facility dedicated to diversity, equity, inclusion and excellence in clinical research. Its patient population is predominantly black with various pulmonary morbidities, and it enrolls minority patients in clinical and device trials to improve understanding of therapeutics and devices in this population. It is committed to timely recruitment and completion of trials with qualified staff.

clinical site servicespatient recruitment

Cumberland Pharmaceuticals Inc. is an innovation-driven biopharmaceutical company based in Nashville, Tennessee, and publicly listed on Nasdaq under CPIX. For over 25 years it has improved patient care through the delivery of high-quality prescription medicines, and it develops new therapies addressing significant unmet medical needs.

biopharmaceutical developmentdrug development

CytexOrtho is a clinical stage medical device company working to advance orthopaedic treatment options for cartilage repair, leveraging tissue regeneration work of Dr. Farshid Guilak, Dr. Bradley Estes, and Dr. Frank Moutos. Its lead product, the ReNew Hip implant, is an acellular implant to restore hip joint health in young patients, and is in an FDA-approved pilot clinical trial. The company is also testing its technology for other joints such as knees and shoulders.

cartilage repairmanufacturing processesmedical device developmenttissue regeneration

CytoAstra is developing the Cytophone platform, which uses In Vivo Photoacoustic Flow Cytometry (PAFC) for early diagnosis of life-threatening diseases including cancers, infections, and cardiovascular disorders, with a focus on melanoma, malaria, and strokes. The technology is noninvasive, label-free, and operates through intact skin using a laser and ultrasound transducers. CytoAstra is also developing a therapeutic device that can detect and treat cancer and infected cells using photoacoustic and photothermal technologies.

In Vivo Photoacoustic Flow Cytometry (PAFC)medical device developmentphotoacoustic detectionphotothermal technologies

Cytokind develops NB-UVB light therapy devices for dermatology and autoimmune conditions, offering home and clinical phototherapy products. The company states its research in clinical trials and serum biomarkers explores pathways upstream of systemic inflammation common to autoimmune diseases, and that its lights require a prescription from a care provider.

phototherapy device developmentserum biomarker research

Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology. It discovers, develops, and commercializes potential medicines for diseases of impaired muscle function, including heart failure, hypertrophic cardiomyopathy (HCM), and neuromuscular diseases such as ALS. Its research focuses on modulating proteins in the sarcomere, including myosin and troponin, and it has a pipeline of small molecule muscle activators and inhibitors.

commercialization of medicinesdrug developmentdrug discoverymuscle biology research

Dade Florida Clinical Research conducts clinical trials that advance medical knowledge and improve patient care. The site states it has over a decade of experience and specializes in Phase I-IV trials, with a mission focused on patient safety, integrity, and innovation. It is located in Miami, Florida, and offers studies across multiple therapeutic areas with a patient-centered, compassionate approach.

EKGslaboratory testspatient carepatient screeningPhase I-IV trials

Dawes Fretzin Clinical Research is a clinical research group specializing in dermatology with 24 years of clinical trial experience and 500 total clinical trials as of February 2024. The group has primary investigators Scott Fretzin, MD, Kenneth Dawes, MD, and Michael Sheehan, MD, along with 13 sub-investigators, 8 study coordinators, and 1 regulatory coordinator. It conducts Phase I-IV trials as well as pharmacokinetic, pharmacodynamic, and bioavailability/bioequivalence studies.

21 CFR Part 11CITIElectronic Data Capture (EDC)GCPHIPAAIATAInformed Consentpatient enrollmentSAE Reporting

Day One Biopharmaceuticals is a biopharmaceutical company focused on advancing first- or best-in-class targeted medicines for childhood and adult diseases, particularly cancer. Founded to address the lack of new therapies from the traditional drug development model, it develops new medicines for people of all ages with life-threatening diseases. The company is now part of Servier Group and is based in Brisbane, California.

drug developmentoncology research

Deep Blue Retina is a retinal surgery clinic serving the Midsouth, committed to eye care for adult and pediatric patients. It provides medical and surgical solutions for complex retinal cases, including retinal detachment repair and complex cataract, and long-term care for chronic conditions such as macular degeneration, diabetes-related vision loss, and glaucoma. It was created in 2019 by Dr. Jorge Calzada and is involved in clinical research trials.

cataract surgeryclinical researchretinal surgery

Diakonos Oncology is a clinical-stage biotechnology company developing a Dendritic Cell Vaccine (DCV) called DOC1021 (also known as dubodencel) for difficult-to-treat cancers. Its proprietary patented 'double-loading' technique tricks the body into perceiving cancer cells as virally infected cells. The company received FDA Fast Track designation and is based on research conducted at Baylor College of Medicine, working with institutions such as MD Anderson and UTHealth Houston.

dendritic cell immunotherapydouble-loading vaccine technique

Dialectic Therapeutics is a clinical-stage biotechnology company based in Dallas, Texas, dedicated to developing innovative anti-cancer drugs. Its lead candidate, DT2216, is built on its proprietary Antiapoptotic Protein Targeted Degradation (APTaD™) technology platform and selectively induces cancer cells to degrade BCL-XL. DT2216 is in Phase 1/2 clinical trials for Fibrolamellar Carcinoma and Platinum-Resistant Ovarian Cancer.

drug developmentmedicinal chemistryprotein degradation

Diamond Therapeutics is a psychedelic pharmaceutical company developing safe, FDA, EMA and Health Canada approved therapies for neuropsychiatric conditions, starting with sub-perceptual psilocybin-based medicines. Its first clinical program focuses on accessible psilocybin-based drugs intended to deliver rapid therapeutic outcomes without perceptual side effects. It is also advancing a pipeline of tryptamine analogs and small organic molecules that modulate selective serotonin receptors and neurotrophic receptor signalling.

drug discoveryformulation developmentpre-clinical and clinical neuropsychiatric drug development